Filler or Facelift? What the Science Actually Says

The evidence behind a question every patient deserves an honest answer to.

Few questions come up more often in consultation than this one: whether years of filler make surgery unnecessary, or whether it’s reasonable simply to keep going.

It’s an important question, and it deserves an evidence-based answer rather than a commercially convenient one. The relationship between injectable fillers and surgical facial rejuvenation (rhytidectomy, commonly called a facelift) is more complex than most patients — and, frankly, many practitioners — appreciate. Understanding it properly may influence not only the treatment you have today, but the options available to you years from now.

The myth of temporary filler: what MRI actually shows

The assumption underlying the injectable industry is that hyaluronic acid filler is temporary. Patients are routinely told it dissolves within twelve to eighteen months and can be reversed with hyaluronidase if needed. The published imaging evidence challenges that assumption substantially.

A 2024 study published in Plastic and Reconstructive Surgery — Global Open, by Australian radiologists with imaging performed at Gold Coast University Hospital, used MRI to review 33 patients who had received mid-face HA filler and were imaged two or more years after their last injection. Filler was detectable in all 33. Twenty-one had not been injected for two to five years and twelve for more than five years, with some at eight to fifteen years; in one patient, product was still visible fifteen years after her last treatment.

This isn’t an outlier finding. It is the largest MRI cohort addressing this specific question, and its conclusion is unambiguous: HA filler remained detectable at two years or more in every patient imaged.

The locations of retained filler are instructive for anyone planning surgery. Product was identified in the deep medial cheek, the medial and lateral SOOF (suborbicularis oculi fat), the buccal compartment, and the pyriform, infraorbital, middle cheek and temporolateral cheek fat compartments — precisely the anatomical regions I work in during a deep plane facelift. Where those spaces are occupied by persistent or migrated filler, assessing true volume deficiency accurately becomes harder, and the dissection itself is more difficult.

Migration is separately documented on imaging, though that evidence needs reading carefully. A prospective study in the Aesthetic Surgery Journal imaged 32 patients who had presented with complications after facial injection with permanent fillers, comparing clinical examination against MRI across 107 site-specific evaluations. Agreement between the two was strong for uncomplicated deposits, but only slight — 9% — for migration. That study did not examine HA, and every patient in it had presented with a problem, so it tells us nothing about how often filler migrates in the general population. What it does show is that where migration has occurred, examining a face from the outside is an unreliable way of establishing where the product has gone.

What this means for facelift surgery

The surgical consequences of a prior filler history are increasingly documented. A survey of members of The Aesthetic Society, published in Aesthetic Surgery Journal Open Forum, found that 51.9% of responding members reported that a history of panfacial filler injections increased the difficulty of performing facelifts. The most common reason given was distortion of the tissue planes from scarring (50%), followed by technical difficulty raising healthy flaps (30.1%). A large subset — 39.7% — believed a history of panfacial filler increased postoperative complication rates, the complications most commonly nominated being undesirable palpability or visibility of filler (32.7%), compromised flap vascularity (15.4%) and decreased longevity of the lifting effect (9.6%).

It is worth being clear about what that study is: surveyed surgeon opinion, not measured complication data. It reflects what a large group of experienced operators believe they encounter, which is useful, but it is not the same as a controlled comparison.

The vascularity finding deserves particular emphasis. Filler injected in prior years, particularly in the nasolabial and perioral regions, can cause subclinical vascular injury. Many patients who have had such an injury don’t recall its true nature and don’t mention it at a facelift consultation. With no physical evidence of the dermal injury and limited recollection on the patient’s part, it can be impossible for a subsequent surgeon to identify past dermal vascular changes that may affect the vascularity of the facial flap. This is a real surgical consideration rather than a theoretical one.

The survey also found that the products believed to cause the greatest surgical difficulty weren’t hyaluronic acid: 38.5% of respondents nominated calcium hydroxylapatite and 35.9% polymethylmethacrylate. That distinction between product categories matters for patients planning surgery in the medium to long term.

Biostimulators: a different problem entirely

I want to address biostimulators separately, because they are fundamentally different from HA filler and are increasingly common.

Products in this category — poly-L-lactic acid and calcium hydroxylapatite — work by stimulating the body’s own collagen production. The result is not volumisation as such but semi-permanent tissue change: new collagen laid down in the treated compartments, accompanied by a variable degree of fibrosis. The survey data is consistent with what I observe clinically, in that calcium hydroxylapatite ranked among the products most likely to increase surgical difficulty, which fits with its fibrogenic tissue effect.

Unlike HA filler, biostimulators cannot be dissolved. The tissue change they produce in the planes I operate in is not reversible. For patients who are planning facelift surgery within the next several years, that warrants careful consideration before proceeding. It doesn’t make surgery impossible. It makes it harder: the tissue planes are stiffer, dissection takes longer, and the margin for error narrows.

My preoperative protocol: filler dissolution before surgery

Given all of the above, I routinely recommend preoperative filler dissolution with hyaluronidase for patients with a significant prior filler history, ideally three to six months before surgery. This isn’t because filler is inherently dangerous, or because I’m opposed to injections. It’s because I need an accurate picture of where a patient’s natural volume loss genuinely lies.

When I perform fat grafting as part of a total facial rejuvenation procedure, I need to know which mid-face compartments have atrophied and require structural grafting. If persistent or migrated filler is creating a false impression of volume in those spaces, the grafting plan will be inaccurate. Dissolution resets the tissue environment and gives me a reliable baseline from which to plan.

It may be advisable to wait longer than a product’s expected duration of effect before undergoing surgery, and patients should be told that filler may still be present beyond its predicted lifespan. I discuss this openly with every relevant patient in consultation, including the possibility that even after dissolution some residual product may remain in the deeper tissue planes, and that I will account for this during the operation.

Where filler still has a genuine role

None of this is an argument against filler. Used selectively — the right product, the right depth, the right anatomical location, by a clinician who understands the anatomy and the downstream implications — injectable treatment has a role that surgery does not fill at an equivalent stage of ageing.

A precisely placed small volume of HA in the deep pyriform fossa can add anterior cheek projection. Structural tear trough support at the correct subperiosteal depth has a legitimate role in the right patient, as does selective perioral treatment in skilled hands. The problems arise not from the product category but from the culture of cumulative, high-volume, panfacial injection that has normalised over the past decade — a culture the published evidence now suggests carries meaningful implications for future surgical options.

When surgery is the right answer

There is a threshold beyond which injectable treatment cannot meaningfully replicate what surgery does. That threshold is defined by anatomy, not age. When the retaining ligaments have stretched, the deep fat compartments have atrophied, the platysma has banded, jowls have formed and the brow has descended, these are simultaneous structural changes across multiple anatomical layers. Filler acts on surface contour. It does not reposition descended tissue, retighten lax muscle, restore deep architectural relationships, or act on the jawline durably.

My approach in this setting is what I describe as total facial rejuvenation: a coordinated procedure that addresses the dimensions of facial ageing in a single operative episode. The foundation is an extended deep plane face and neck lift, operating at the level of the retaining ligaments rather than the superficial SMAS plane, repositioning the facial soft tissue composite as a unit. It is a hybrid of techniques refined through training with Rick Warren in Vancouver, George Orfaniotis in London and Ben Talei in Beverly Hills.

To this I add bespoke small-volume autologous fat grafting, placing the patient’s own structural fat in the deep mid-face compartments where volume has been lost. My background in tissue engineering informs how I approach this — the biological behaviour of the graft, the conditions required for successful integration, and how conservatively to place it, since overcorrection is the common failure mode of fat grafting.

Nanofat grafting to the perioral region and anterior neck is used with the aim of improving skin quality over the months following surgery. The evidence base for that effect is still developing, the degree of change differs considerably between individuals, and it is not a substitute for the structural operation. Where brow descent forms part of the ageing picture, as it frequently does, endoscopic brow elevation can be included in the same operative episode.

The intention throughout is to address the face at each relevant anatomical level rather than at the surface alone. What that means for any individual patient depends on their anatomy and how they heal, and can only be assessed in consultation.

A final word on informed decision-making

The evidence I’ve cited here isn’t intended to frighten patients away from injectable treatment. It’s intended to make the conversation more honest. Patients considering ongoing filler maintenance, or planning surgery at some point in the future, deserve to know that the product being injected may still be present a decade later, that it may migrate from where it was placed, and that its presence in the surgical tissue planes carries real implications for a future procedure.

That’s the conversation I have in consultation. It’s the only conversation that genuinely serves a patient’s long-term interests.

Risks of surgery

Facelift surgery is a major surgical procedure performed under general anaesthesia, and it carries real risks, which are discussed with you in full at consultation and again before surgery. Complications can include bleeding, haematoma — a collection of blood beneath the skin, and the most common significant complication of facelift surgery — infection, wound healing difficulties, scarring, asymmetry, changes in skin sensation, and injury to the branches of the facial nerve, which is uncommon and often temporary but can be serious. Fat grafting carries additional risks, including partial resorption of the grafted fat, irregularity or overcorrection, and the possible need for further grafting. Recovery takes weeks rather than days, and further surgery is sometimes required. Outcomes vary between individuals according to anatomy, healing and other factors, and no result can be guaranteed.

Hyaluronidase dissolution is a separate procedure with its own risks, including allergic reaction and loss of volume that a patient may have wished to keep. It is discussed on its own terms before it is undertaken.

Before proceeding, a referral from your GP or another registered medical practitioner is required, and a seven-day cooling-off period applies. All of this will be discussed with you carefully in advance.

I consult at The Coastal Clinic on the Gold Coast and Fraser-Kirk Plastic Surgery on the Sunshine Coast. For patients with a significant filler history who are considering facelift surgery, preoperative assessment and a dissolution plan form part of my standard consultation process.

Dr David Sparks — MBBS(Hons) MS(Plast) PhD FRACS(Plast) — Specialist Plastic Surgeon, MED0001863770

All surgery and invasive procedures carry risks. Before proceeding, you should seek a second opinion from an appropriately qualified health practitioner.